New antibody combo aims to shrink Hard-to-Treat prostate tumors

NCT ID NCT05125016

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two experimental drugs, REGN4336 and REGN5678, in men with metastatic castration-resistant prostate cancer that has worsened despite prior treatment. The first part finds safe doses, and the second part checks how well the combination shrinks tumors. About 228 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN4336 and REGN5678 (bispecific antibodies)
What this could lead to: If successful, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drugs may not prove effective or may cause unexpected side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Atrium Health Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Fox Chase Cancer Center
WITHDRAWN

Philadelphia, Pennsylvania, 19111, United States
Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Norton Cancer Institute
RECRUITING

Louisville, Kentucky, 40207, United States
Penn Medicine University of Pennsylvania Health System
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08901, United States
Stanford University Medical Center - Blake Wilbur Drive
RECRUITING

Palo Alto, California, 94304, United States
The Ohio State University James Cancer Hospital
RECRUITING

Columbus, Ohio, 43210, United States
Thomas Jefferson University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of Maryland Greenebaum Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States
Yale University Hospital
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.